Wellington Management Group LLP Buys 718,515 Shares of Boston Scientific Co. (NYSE:BSX)

Wellington Management Group LLP grew its stake in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 2.2% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 32,820,828 shares of the medical equipment provider's stock after acquiring an additional 718,515 shares during the quarter. Wellington Management Group LLP owned about 2.23% of Boston Scientific worth $2,750,385,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of BSX. Triad Wealth Partners LLC purchased a new stake in Boston Scientific during the 2nd quarter valued at $26,000. Values First Advisors Inc. bought a new position in shares of Boston Scientific during the third quarter valued at $28,000. Andra AP fonden purchased a new stake in shares of Boston Scientific during the second quarter valued at $29,000. E Fund Management Hong Kong Co. Ltd. bought a new stake in Boston Scientific in the 3rd quarter worth about $30,000. Finally, Capital Performance Advisors LLP purchased a new position in Boston Scientific in the 3rd quarter worth about $30,000. Hedge funds and other institutional investors own 89.07% of the company's stock.

Analyst Upgrades and Downgrades

BSX has been the subject of a number of research analyst reports. StockNews.com lowered shares of Boston Scientific from a "buy" rating to a "hold" rating in a research note on Monday, November 4th. Needham & Company LLC restated a "hold" rating on shares of Boston Scientific in a report on Wednesday, November 27th. Morgan Stanley boosted their target price on shares of Boston Scientific from $92.00 to $100.00 and gave the company an "overweight" rating in a research note on Thursday, October 24th. Royal Bank of Canada raised their price target on Boston Scientific from $95.00 to $98.00 and gave the stock an "outperform" rating in a research note on Thursday, October 24th. Finally, Mizuho lifted their price objective on Boston Scientific from $100.00 to $110.00 and gave the stock an "outperform" rating in a report on Thursday, October 24th. Four analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Boston Scientific presently has an average rating of "Moderate Buy" and an average price target of $93.39.

Boston Scientific Price Performance

Shares of NYSE BSX traded down $0.46 during mid-day trading on Friday, reaching $90.07. The company's stock had a trading volume of 3,302,016 shares, compared to its average volume of 4,982,464. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.48 and a quick ratio of 1.02. Boston Scientific Co. has a 52 week low of $54.52 and a 52 week high of $91.93. The stock has a fifty day moving average of $87.27 and a two-hundred day moving average of $81.16. The firm has a market capitalization of $132.75 billion, a PE ratio of 74.44, a P/E/G ratio of 2.68 and a beta of 0.80.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.59 by $0.04. Boston Scientific had a net margin of 11.26% and a return on equity of 17.23%. The business had revenue of $4.21 billion during the quarter, compared to analyst estimates of $4.04 billion. During the same period last year, the firm posted $0.50 EPS. The company's revenue was up 19.3% on a year-over-year basis. As a group, sell-side analysts anticipate that Boston Scientific Co. will post 2.46 EPS for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In other news, EVP Wendy Carruthers sold 6,983 shares of the business's stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $90.78, for a total value of $633,916.74. Following the sale, the executive vice president now directly owns 29,308 shares in the company, valued at $2,660,580.24. The trade was a 19.24 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Arthur C. Butcher sold 14,010 shares of the stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $89.27, for a total transaction of $1,250,672.70. Following the completion of the transaction, the executive vice president now directly owns 978 shares of the company's stock, valued at approximately $87,306.06. The trade was a 93.47 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 328,157 shares of company stock worth $27,957,676. Insiders own 0.50% of the company's stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.